RESPONSE AFTER NON-FINAL ACTION - ENTERED
final action
on 04 Jun 2024
Last Applicant/ Owned by
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE
MA
02142
Serial Number
98254371 filed on 03rd Nov 2023
Registration Number
N/A
Correspondent Address
Christina M. Licursi WOLF, GREENFIELD & SACKS, P.C.
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
DELVE
Medical research and development; research and development in the field of computational biology, bioinformatics, genetics, genomics, biotechnology, pharmaceuticals, and therapeutics; platform as a service (PaaS) featuring computer software platforms for drug discovery; pharmaceutical and biopharmaceutical research and development; drug development services, namely, pharmaceutical drug development Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Medical research and development; research and development in the field of computational biology, bioinformatics, genetics, genomics, biotechnology, pharmaceuticals, and therapeutics; platform as a service (PaaS) featuring computer software platforms for drug discovery; pharmaceutical and biopharmaceutical research and development; drug development services, namely, pharmaceutical drug development services; development of pharmaceuticals and therapeutic agents for others, namely, development of pharmaceutical preparations and medicines; platform as a service (PaaS) featuring computer software platforms for enabling research and development of pharmaceutical data in the field of computational biology, bioinformatics, genetics, genomics, biotechnology and pharmaceuticals; DNA, RNA, and genomic analysis and sequencing services for medical research purposes; none of the foregoing relating to finding people scientific studies to participate in or recruiting participants for scientific studies
First Use Date in General
11th 000101
First Use Date in Commerce
11th 000101
Class [005]
Pharmaceutical Products
Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceuticals for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases
First Use Date in General
11th 000101
First Use Date in Commerce
11th 000101
Mark Details
Serial Number
No 98254371
Mark Type
No Service Mark
Attorney Docket Number
No F20782000200
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 04th Jun 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 03rd Jun 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 03rd Jun 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 04th Mar 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 04th Mar 2024 | NON-FINAL ACTION E-MAILED |
| 04th Mar 2024 | NON-FINAL ACTION WRITTEN |
| 26th Jan 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 26th Jan 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 26th Jan 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 24th Jan 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |